Melanie Subramanian1, Timothy McMurry2, Bryan F Meyers1, Varun Puri1, Benjamin D Kozower3. 1. Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia. 3. Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri. Electronic address: kozowerb@wustl.edu.
Abstract
BACKGROUND: Lobectomy has been compared with sublobar resection for the treatment of stage IA non-small cell lung cancer (NSCLC). Accurate long-term data are lacking on the risk of recurrence in routine clinical practice. This study used a unique and representative dataset to compare recurrence, overall survival (OS), and lymph node staging between lobectomy and sublobar resection. METHODS: The American College of Surgeons performed a Special Study of the National Cancer Data Base, by reabstracting records to augment NSCLC data with enhanced information on preoperative comorbidity and cancer recurrence from 2007 to 2012. For patients treated with lobectomy or sublobar resection (wedge resection or segmentectomy) for clinical stage IA NSCLC, propensity matching and competing risks models compared 5-year OS and risk of cancer recurrence. Secondary measures included lymph nodes collected, pathologic upstaging, and surgical margin status. RESULTS: A total of 1,687 patients with stage IA NSCLC were identified (1,354 who underwent lobectomy, and 333 who had sublobar resections). Propensity matching yielded 325 pairs. Lobectomy and sublobar resection groups had similar 5-year OS (61.8% vs 55.6%, p = 0.561). The sublobar group had a 39% increased risk of NSCLC recurrence (hazard ratio, 1.39; 95% confidence interval, 1.04 to 1.87). Median lymph node counts were higher for lobectomy-treated patients (7 [3, 10] vs 1 [0, 4], p < 0.001)]. CONCLUSIONS: In an enhanced national dataset representative of outcomes for stage IA NSCLC, sublobar resection was associated with a 39% increased risk of cancer recurrence. The majority of patients treated with sublobar resection had an inadequate lymph node assessment. These real-world results must be considered when existing clinical trial results comparing these treatments are extrapolated for clinical use.
BACKGROUND: Lobectomy has been compared with sublobar resection for the treatment of stage IA non-small cell lung cancer (NSCLC). Accurate long-term data are lacking on the risk of recurrence in routine clinical practice. This study used a unique and representative dataset to compare recurrence, overall survival (OS), and lymph node staging between lobectomy and sublobar resection. METHODS: The American College of Surgeons performed a Special Study of the National Cancer Data Base, by reabstracting records to augment NSCLC data with enhanced information on preoperative comorbidity and cancer recurrence from 2007 to 2012. For patients treated with lobectomy or sublobar resection (wedge resection or segmentectomy) for clinical stage IA NSCLC, propensity matching and competing risks models compared 5-year OS and risk of cancer recurrence. Secondary measures included lymph nodes collected, pathologic upstaging, and surgical margin status. RESULTS: A total of 1,687 patients with stage IA NSCLC were identified (1,354 who underwent lobectomy, and 333 who had sublobar resections). Propensity matching yielded 325 pairs. Lobectomy and sublobar resection groups had similar 5-year OS (61.8% vs 55.6%, p = 0.561). The sublobar group had a 39% increased risk of NSCLC recurrence (hazard ratio, 1.39; 95% confidence interval, 1.04 to 1.87). Median lymph node counts were higher for lobectomy-treated patients (7 [3, 10] vs 1 [0, 4], p < 0.001)]. CONCLUSIONS: In an enhanced national dataset representative of outcomes for stage IA NSCLC, sublobar resection was associated with a 39% increased risk of cancer recurrence. The majority of patients treated with sublobar resection had an inadequate lymph node assessment. These real-world results must be considered when existing clinical trial results comparing these treatments are extrapolated for clinical use.
Authors: Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Francis C Nichols; Shauna L Hillman; Dwight E Heron; Bryan F Meyers; Thomas A DiPetrillo; David R Jones; Sandra L Starnes; Angelina D Tan; Benedict D T Daly; Joe B Putnam Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: Heber MacMahon; David P Naidich; Jin Mo Goo; Kyung Soo Lee; Ann N C Leung; John R Mayo; Atul C Mehta; Yoshiharu Ohno; Charles A Powell; Mathias Prokop; Geoffrey D Rubin; Cornelia M Schaefer-Prokop; William D Travis; Paul E Van Schil; Alexander A Bankier Journal: Radiology Date: 2017-02-23 Impact factor: 11.105
Authors: Timothy L McMurry; Puja M Shah; Pamela Samson; Clifford G Robinson; Benjamin D Kozower Journal: J Thorac Cardiovasc Surg Date: 2017-04-05 Impact factor: 5.209
Authors: Amgad El-Sherif; Hiran C Fernando; Ricardo Santos; Brian Pettiford; James D Luketich; John M Close; Rodney J Landreneau Journal: Ann Surg Oncol Date: 2007-05-16 Impact factor: 5.344
Authors: Christopher Cao; David H Tian; Ben Fu; James Huang; Neel K Ranganath; Dominique Gossot Journal: J Thorac Dis Date: 2018-09 Impact factor: 2.895
Authors: Joshua R Niska; Terence T Sio; Thomas B Daniels; Staci E Beamer; Dawn E Jaroszewski; Helen J Ross; Harshita R Paripati; Steven E Schild Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895
Authors: Brendan T Heiden; Daniel B Eaton; Su-Hsin Chang; Yan Yan; Martin W Schoen; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri Journal: Ann Surg Date: 2021-05-11 Impact factor: 12.969
Authors: Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005
Authors: Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Kristen E Rhodin; Thomas A D'Amico; David H Harpole; Chi-Fu Jeffrey Yang; Betty C Tong Journal: Chest Date: 2020-07-08 Impact factor: 9.410